Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

IRONWOOD PHARMACEUTICALS INC

CIK 1446847 IRWD·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Material weakness 10-K
  2. Finance chief departure 8-K +76d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Finance chief departure elevated Filing comparison

IRONWOOD PHARMACEUTICALS INC's Chief Financial Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Finance chief departure elevated Filing comparison

IRONWOOD PHARMACEUTICALS INC's Chief Financial Officer departed, replaced on an interim basis

Evidence
Interim only
Yes
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
elevated
Source
SEC 8-K item code
Successor named
No
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗

Material weakness Filing comparison

IRONWOOD PHARMACEUTICALS INC reported internal control effective again after a material weakness

Material weakness in internal control → Internal control reported effective

The weakness was first reported on 2025-03-31 — 332 days and 1 annual report before this one.

We remediated the material weaknesses during the year ended December 31, 2025 and concluded that our internal control over financial reporting was effective as of December 31, 2025. For further discussion of those material weaknesses and our remediation efforts, see Part II, Item 9A, under the heading “Controls and Procedures” in this Annual Report on Form 10-K. We expect that the price of our Class A Common Stock will fluctuate substantially. The market price of our Class A Common Stock may be highly volatile…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-03-31
Prior form
10-K
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
Yes
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
1
Weakness days reported
332
Weakness first reported
2025-03-31
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗